USPTO Art Unit 1642 Prosecution Statistics

Art Unit Information

Art Unit: 1642
Group: 1640
Tech Center: 1600
Total Cases: 11,782
Last Active: December 2024

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18991315Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofDecember 2024March 2025Allow310NoNo
18923463POLYNUCLEOTIDES ENCODING PARAOXONASE FUSION POLYPEPTIDESOctober 2024December 2024Allow100NoNo
18898854Antibodies Targeting ActRIIA and ActRIIBSeptember 2024December 2024Abandon300NoNo
18890453ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATIONSeptember 2024March 2025Allow610YesNo
18810362HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6August 2024May 2025Allow820NoNo
18759723ANTIBODY-DRUG CONJUGATES AND USES THEREOFJune 2024December 2024Allow610YesNo
18749771COMPOSITIONS AND METHODS FOR DETECTING PANCREATIC CANCERJune 2024June 2025Allow1211YesNo
18749504DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITYJune 2024January 2025Allow710YesNo
18749522DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITYJune 2024March 2025Allow910YesNo
18674612DOSAGE OF CLAUDIN-6 CONJUGATES FOR CANCER TREATMENTMay 2024April 2025Allow1120YesNo
18644619SYSTEM AND SENSOR ARRAYApril 2024February 2025Allow1012NoNo
18628200RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERSApril 2024February 2025Allow1110NoNo
18593028ATP-Dependent Agonists of Immune Cells Function as Anticancer AgentsMarch 2024August 2024Allow500NoNo
18592208METHODS OF TREATING TUMORFebruary 2024March 2025Allow1210NoNo
18429111[3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDJanuary 2024June 2025Abandon1621NoNo
18427038ANTI-DCLK1 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2024June 2025Allow1601NoNo
18426324PE-STOP Gene Editing System and Gene Knockout Method and ApplicationJanuary 2024April 2025Abandon1521YesNo
18417299ANTI-AMYLOID BETA PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOFJanuary 2024June 2024Allow511YesNo
18412245COMPOSITIONS AND METHODS COMPRISING SFRP2 ANTAGONISTSJanuary 2024November 2024Allow1000NoNo
18408377METHODS OF USING ANTI-SP17 IMMUNOTHERAPEUTICSJanuary 2024November 2024Allow1010YesNo
18405910BINDING MOLECULESJanuary 2024June 2024Allow601YesNo
18396461ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODYDecember 2023January 2025Allow1310NoNo
18393153METHODS FOR MODULATING AN IMMUNE RESPONSEDecember 2023December 2024Abandon1211NoNo
18542441T CELL RECEPTORS AND FUSION PROTEINS THEREOFDecember 2023April 2024Allow400NoNo
18541600COMBINATION THERAPIES FOR TREATING CANCERDecember 2023March 2025Abandon1510NoNo
18537973COMPOSITION OF BL-8040December 2023October 2024Allow1020YesNo
18538242ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING MAGE-ADecember 2023December 2024Allow1221YesNo
18532450SYSTEMS AND METHODS FOR BARRETT'S ESOPHAGUS PATHOGENESIS AND ESOPHAGEAL ADENOCARCINOMA PROGRESSION REVEALING MARKERSDecember 2023March 2025Allow1621NoNo
18531287DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIESDecember 2023August 2024Abandon800NoNo
18529758COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTSDecember 2023February 2025Allow1420NoNo
18529537MYCOVIRUS-INDUCED GENE SILENCING VECTOR, CONSTRUCTION METHOD AND APPLICATION THEREOFDecember 2023August 2024Allow810NoNo
185246133E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic colorectal cancer modelNovember 2023March 2025Allow1610NoNo
18523859IMMUNOASSAY-BASED DETERMINATION OF IN-SOLUTION BINDING KINETICSNovember 2023May 2025Allow1810NoNo
18516168RESPONSE TO EGFR BLOCKADENovember 2023April 2025Abandon1710NoNo
18512556FC FUSION MOLECULES AND USES THEREOFNovember 2023June 2024Allow701YesNo
18509504Conjugate MoleculesNovember 2023June 2024Allow720NoNo
18501589Tetravalent FZD and WNT Co-receptor Binding Antibody Molecules and Uses ThereofNovember 2023January 2025Abandon1511YesNo
183864215-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-2-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow310YesNo
18498843ENGINEERED SIRPa VARIANTS AND METHODS OF USE THEREOFOctober 2023December 2024Allow1341YesNo
18381344INTRACELLULAR DELIVERY COMPOSITIONSOctober 2023April 2025Allow1821YesNo
18487818METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTHOctober 2023April 2025Abandon1810NoNo
18482643Targeting Intracellular Target-Binding Determinants with Intracellular AntibodiesOctober 2023June 2024Allow811NoNo
18477722COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITORSeptember 2023June 2024Abandon800NoNo
18475552Anti-TIM-3 Antibodies and Use ThereofSeptember 2023February 2025Abandon1710NoNo
18372933DEVICE AND METHOD FOR DETECTION OF ANALYTESSeptember 2023December 2024Allow1510NoNo
18471388HUMANIZED ANTI-IL-1R3 ANTIBODY AND METHODS OF USESeptember 2023March 2024Allow610YesNo
18368138[3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDSeptember 2023October 2024Abandon1311NoNo
18462648OVARIAN CANCER VACCINESSeptember 2023March 2025Allow1820NoNo
18463209HETERODIMERIC PROTEINSSeptember 2023May 2025Allow2010NoNo
18459857Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofSeptember 2023June 2024Abandon1010NoNo
18460221SYSTEM AND SENSOR ARRAYSeptember 2023March 2024Allow610YesNo
18460254METHODS AND DEVICES FOR ASSAYING A BIOLOGICAL SAMPLESeptember 2023July 2024Allow1031YesNo
18459842METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIESSeptember 2023February 2025Abandon1800NoNo
18239348NOVEL POTASSIUM CHANNEL INHIBITORSAugust 2023November 2023Allow310NoNo
18456044NOVEL THI-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS AND USE OF SAMEAugust 2023May 2025Allow2130NoNo
18456262ANTI-SEZ6 ANTIBODY DRUG CONJUGATESAugust 2023July 2024Allow1020NoNo
18452972METHODS OF TREATING CANCERAugust 2023May 2025Abandon2111NoNo
18451990TREATMENT OF LAG-3 POSITIVE TUMORSAugust 2023March 2024Allow700NoNo
18546413PARAOXONASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODSAugust 2023July 2024Allow1211NoNo
18263430ANTI-NECTIN-4-ANTIBODIES AND USES THEREOFJuly 2023March 2024Allow810NoNo
18227057METHODS FOR MODULATING AN IMMUNE RESPONSEJuly 2023January 2024Allow621NoNo
18356985CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINSJuly 2023June 2025Allow2300NoNo
18357013CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINSJuly 2023June 2024Allow1111YesNo
18348398Early and Non Invasive Method for Assessing a Subject's Risk of Having Pancreatic Ductal Adenocarcinoma and Methods of Treatement of Such DiseaseJuly 2023July 2024Allow1200NoNo
18348948ENGINEERED NUCLEASES, COMPOSITIONS, AND METHODS OF USE THEREOFJuly 2023March 2024Allow911NoNo
18270521COMPOSITION OF BL-8040June 2023January 2025Allow1910NoNo
18345587ANTI-TIGIT ANTIBODIES AND METHODS OF USEJune 2023October 2024Abandon1500NoNo
18340774NEUROPILIN-1-PEPTIDE BASED ANTIBODY, HIGHLIGHTING NEW EPITOPE ASSOCIATED TO GLYCOSAMINOGLYCAN-MODIFIED NEUROPILIN-1 AND METHODS OF USE THEREOFJune 2023December 2023Allow500NoNo
18213132HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOFJune 2023February 2025Allow2020NoNo
18211038Methods of Assaying Neoplastic and Neoplasia-Related Cells and Uses ThereofJune 2023January 2025Allow1920NoNo
18330844USE OF an anti-P-selectin antibodyJune 2023April 2025Abandon2301NoNo
18205581METHOD FOR FLUORESCENT IMMUNOASSAY (FIA) AND CHEMILUMINESCENT IMMUNOASSAY (CLIA) BASED ON ELECTROKINETIC ACCELERATIONJune 2023October 2023Allow400NoNo
18329252IN SITU HEAT INDUCED ANTIGEN RECOVERY AND STAINING APPARATUS AND METHODJune 2023March 2025Allow2210NoNo
18326826HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLSMay 2023June 2024Allow1220NoNo
18325497BIOMARKERS FOR CANCER IMMUNOTHERAPY OUTCOMESMay 2023January 2025Abandon1901NoNo
18323898COMPOSITIONS AND METHODS FOR INHIBITING OR SCREENING FOR CD8 AND METHODS AND ASSAYS FOR DETECTING CD8 IN CELLSMay 2023March 2025Abandon2211NoNo
18200000ANTITUMOR PHARMACEUTICAL COMPOSITION COMPRISING AZVUDINE AND CHEMOTHERAPEUTIC AGENTMay 2023January 2025Allow2060NoNo
18316628IMMUNOTHERAPY TARGETING TUMOR NEOANTIGENIC PEPTIDESMay 2023August 2024Allow1520YesNo
18036610METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTHMay 2023May 2025Abandon2520YesNo
18143978DOSING PARAMETERS FOR CD47 TARGETING THERAPIES TO HEMATOLOGIC MALIGNANCIESMay 2023November 2023Allow610YesNo
18309488USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMABApril 2023October 2024Abandon1821NoNo
18309037ANTIBODIES BINDING TO GPRC5DApril 2023February 2024Abandon1000NoNo
18308623HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENSApril 2023March 2025Allow2211NoNo
18306562A BISPECIFIC ANTAGONIST COMPRISING A LAG-3 BINDING DOMAINApril 2023June 2025Allow2510NoNo
18300825TREATMENT OF METASTATIC BREAST CANCERApril 2023May 2025Abandon2610NoNo
18301141USE OF BAZ1B_K426hy AND POLYCLONAL ANTIBODY THEREOF IN PREPARATION OF PRODUCT FOR TUMOR DETECTIONApril 2023August 2024Allow1610YesNo
18134293METHODS OF TREATING COLON CANCER USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPYApril 2023December 2024Abandon2010NoNo
18133822TREATMENT OF CANCER WITH ANTI-GITR AGONIST ANTIBODIESApril 2023September 2024Abandon1710NoNo
18298807THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUSApril 2023October 2024Allow1810NoNo
18298310ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAMEApril 2023December 2023Allow900NoNo
18295739SPR-BASED BRIDGING ASSAY FORMAT FOR DETERMINING THE BIOLOGICAL ACTIVITY OF MULTIVALENT, MULTISPECIFIC MOLECULESApril 2023February 2025Abandon2310NoNo
18126275SYNTHETIC LETHALITY AND THE TREATMENT OF CANCERMarch 2023March 2025Abandon2411NoNo
18186762Immunotherapy Methods for Patients Whose Tumors Carry a High Passenger Gene Mutation BurdenMarch 2023October 2024Allow1910NoNo
18185736IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOFMarch 2023August 2024Allow1710NoNo
18185805COMPOSITION AND METHOD OF USE RECOMBINANT FUSION PROTEIN TO GENERATE CAR-IMMUNE CELLSMarch 2023February 2024Allow1110YesNo
18183878IMMUNITY ENHANCING AGENT FOR CANCER BY ALLERGIN-1 ANTAGONISTMarch 2023June 2025Abandon2701NoNo
18183467TREATMENT WITH ANTI-VEGF ANTIBODIESMarch 2023December 2024Abandon2101NoNo
18183107TRISPECIFIC BINDING PROTEINS, METHODS, AND USES THEREOFMarch 2023April 2024Allow1310NoNo
18182211CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTORMarch 2023January 2025Allow2310NoNo
18181661IMMUNOSTIMULATORY AGONISTIC ANTIBODIES FOR USE IN TREATING CANCERMarch 2023October 2024Abandon1901NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1642.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
132
Examiner Affirmed
90
(68.2%)
Examiner Reversed
42
(31.8%)
Reversal Percentile
47.5%
Lower than average

What This Means

With a 31.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1166
Allowed After Appeal Filing
215
(18.4%)
Not Allowed After Appeal Filing
951
(81.6%)
Filing Benefit Percentile
3.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1642 - Prosecution Statistics Summary

Executive Summary

Art Unit 1642 is part of Group 1640 in Technology Center 1600. This art unit has examined 11,782 patent applications in our dataset, with an overall allowance rate of 50.2%. Applications typically reach final disposition in approximately 34 months.

Comparative Analysis

Art Unit 1642's allowance rate of 50.2% places it in the 7% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1642 receive an average of 1.96 office actions before reaching final disposition (in the 63% percentile). The median prosecution time is 34 months (in the 23% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.